Integrated Biological Markers for the Prediction of Treatment Response in Depression: A Pilot Study
Latest Information Update: 27 Dec 2023
At a glance
- Drugs Escitalopram (Primary) ; Aripiprazole
- Indications Major depressive disorder
- Focus Biomarker; Therapeutic Use
- Acronyms CAN-BIND-1
- 20 Dec 2023 Results assessing SGK1 mRNA expression from peripheral blood, and left and right hippocampal volume at baseline, as well as change in these markers over the first 8 weeks of a 16-week open-label trial of escitalopram as part of the Canadian Biomarker Integration Network in Depression program (MDD [n = 161] and healthy [n = 91] comparison participants, published in the European Neuropsychopharmacology.
- 15 Nov 2023 Results published in the Journal of Clinical Psychiatry
- 01 May 2022 Results assessing relationships between antidepressant treatment outcomes and sexual functioning published in the Journal of Psychopharmacology